Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

E. Lipson · SciRah

Researcher profile · Semantic Scholar

E. Lipson

Share profile

E. Lipson — researcher profile on SciRah

h-index: 53
Works: 139
Citations: 14K

Most-cited papers

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma
H. Tawbi, D. Schadendorf, E. Lipson, P. Ascierto +18 more
2022New England Journal of Medicine1,514 citations Open access
Semantic Scholar
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
P. Nghiem, S. Bhatia, E. Lipson, R. Kudchadkar +27 more
2016New England Journal of Medicine1,129 citations Open access
Semantic Scholar
Cardiovascular toxicities associated with immune checkpoint inhibitors
Jiun-Ruey Hu, Roberta Florido, E. Lipson, J. Naidoo +6 more
2019Cardiovascular Research526 citations Open access
Semantic Scholar
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
L. Heinzerling, P. Ott, F. Hodi, A. Husain +6 more
2016Journal of Immunotherapy for Cancer485 citations Open access
Semantic Scholar
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
L. Cappelli, Anna Kristina Gutierrez, A. Baer, J. Albayda +9 more
2016Annals of the Rheumatic Diseases385 citations Open access
Semantic Scholar
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy.
P. Nghiem, S. Bhatia, E. Lipson, W. Sharfman +27 more
2018Journal of Clinical Oncology336 citations Open access
Semantic Scholar
Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Linda Chen, J. Douglass, L. Kleinberg, Xiao-Bu Ye +10 more
2017International Journal of Radiation Oncology, Biology, Physics310 citations
Semantic Scholar
Tumor Regression and Allograft Rejection after Administration of Anti–PD-1
E. Lipson, S. Bagnasco, Jack Moore, S. Jang +5 more
2016New England Journal of Medicine258 citations Open access
Semantic Scholar
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma
N. Gross, D. Miller, N. Khushalani, V. Divi +25 more
2022New England Journal of Medicine255 citations Open access
Semantic Scholar
Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.
Tanya J. Williams, David R. Benavides, Kelly-Ann Patrice, J. Dalmau +5 more
2016JAMA Neurology249 citations Open access
Semantic Scholar
Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma
Steve Y. Cho, E. Lipson, Hyung-Jun Im, S. Rowe +6 more
2017Journal of Nuclear Medicine224 citations Open access
Semantic Scholar
Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy.
P. Ascierto, I. Melero, S. Bhatia, P. Bono +15 more
2017211 citations
Semantic Scholar
Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation
T. Braaten, J. Brahmer, P. Forde, D. Le +7 more
2019Annals of the Rheumatic Diseases209 citations Open access
Semantic Scholar
Melanoma subtypes demonstrate distinct PD-L1 expression profiles
G. Kaunitz, T. Cottrell, Mohammed T. Lilo, Valliammai Muthappan +15 more
2017Laboratory investigation; a journal of technical methods and pathology195 citations Open access
Semantic Scholar
Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade
S. Berry, Nicolas A. Giraldo, B. Green, T. Cottrell +33 more
2021Science174 citations Open access
Semantic Scholar
Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy.
B. Warner, A. Baer, E. Lipson, C. Allen +13 more
2019The Oncologist170 citations Open access
Semantic Scholar
The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis.
K. Suresh, J. Naidoo, Q. Zhong, Y. Xiong +24 more
2019Journal of Clinical Investigation164 citations Open access
Semantic Scholar
Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
Nicolas A. Giraldo, Peter Nguyen, Elizabeth L. Engle, G. Kaunitz +23 more
2018Journal of Immunotherapy for Cancer158 citations Open access
Semantic Scholar
Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade
J. Stein, E. Lipson, T. Cottrell, P. Forde +11 more
2019Clinical Cancer Research146 citations Open access
Semantic Scholar
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
P. Ascierto, E. Lipson, R. Dummer, J. Larkin +18 more
2023Journal of Clinical Oncology144 citations Open access
Semantic Scholar
Neuropilin-1 is a T cell memory checkpoint limiting long-term anti-tumor immunity
Chang Liu, Ashwin Somasundaram, Sasikanth Manne, A. Gocher +10 more
2020Nature Immunology137 citations Open access
Semantic Scholar
Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
E. Lipson, Mohammed T. Lilo, Aleksandra Ogurtsova, Jessica Esandrio +5 more
2017Journal of Immunotherapy for Cancer137 citations Open access
Semantic Scholar
Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen
L. Cappelli, J. Brahmer, P. Forde, D. Le +5 more
2018Seminars in Arthritis & Rheumatism136 citations Open access
Semantic Scholar
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison
J. Sunshine, Peter Nguyen, G. Kaunitz, T. Cottrell +9 more
2017Clinical Cancer Research130 citations Open access
Semantic Scholar
Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
P. Nghiem, S. Bhatia, E. Lipson, W. Sharfman +25 more
2021Journal for ImmunoTherapy of Cancer118 citations Open access
Semantic Scholar
Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).
E. Lipson, H. Tawbi, D. Schadendorf, P. Ascierto +15 more
2021115 citations
Semantic Scholar
A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse Events.
J. Naidoo, Jiajia Zhang, E. Lipson, P. Forde +16 more
2019The Journal of the National Comprehensive Cancer Network104 citations Open access
Semantic Scholar
Chronic immune checkpoint inhibitor pneumonitis
J. Naidoo, Tricia R. Cottrell, E. Lipson, P. Forde +13 more
2020Journal for ImmunoTherapy of Cancer96 citations Open access
Semantic Scholar
Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series
K. Moseley, J. Naidoo, C. Bingham, M. Carducci +6 more
2018Journal of Immunotherapy for Cancer89 citations Open access
Semantic Scholar
Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial
F. Hodi, H. Kluger, M. Sznol, R. Carvajal +17 more
201688 citations
Semantic Scholar
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade
J. Naidoo, L. Cappelli, P. Forde, Kristen A. Marrone +12 more
2017The Oncologist81 citations Open access
Semantic Scholar
Transcriptional mechanisms of resistance to anti-PD-1 therapy
M. Ascierto, Alvin P. Makohon-Moore, E. Lipson, J. Taube +17 more
2017Clinical Cancer Research78 citations Open access
Semantic Scholar
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding
Lawrence P. Andrews, Ashwin S. Somasundaram, J. Moskovitz, Andrea L. Szymczak-Workman +13 more
2020Science immunology74 citations Open access
Semantic Scholar
Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis
A. Jain, E. Lipson, W. H. Sharfman, S. Brant +1 more
2017World Journal of Gastroenterology74 citations Open access
Semantic Scholar
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.
J. Stein, Abha Soni, L. V. Danilova, T. Cottrell +9 more
2019Annals of Oncology72 citations Open access
Semantic Scholar
Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma
E. Yanik, G. Kaunitz, T. Cottrell, F. Succaria +10 more
2017JAMA Oncology72 citations Open access
Semantic Scholar
Cutaneous eruptions in patients receiving immune checkpoint blockade: Clinicopathologic analysis of the non-lichenoid histologic pattern
G. Kaunitz, Manisha J. Loss, H. Rizvi, S. Ravi +13 more
2017American Journal of Surgical Pathology63 citations Open access
Semantic Scholar
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
J. Naidoo, K. Schreck, W. Fu, Chen Hu +19 more
2021Journal for ImmunoTherapy of Cancer61 citations Open access
Semantic Scholar
Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case series
J. LoPiccolo, M. Schollenberger, S. Dakhil, S. Rosner +5 more
2019Journal of Immunotherapy for Cancer50 citations Open access
Semantic Scholar
Immunotherapy for Merkel cell carcinoma: a turning point in patient care
Isaac S. Chan, S. Bhatia, H. Kaufman, E. Lipson
2018Journal of Immunotherapy for Cancer49 citations Open access
Semantic Scholar
Nivolumab + tacrolimus + prednisone +/− ipilimumab for kidney transplant recipients with advanced cutaneous cancers
K. M. Schenk, J. S. Deutsch, S. Chandra, D. Davar +22 more
2024Journal of Clinical Oncology45 citations Open access
Semantic Scholar
From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real‐world setting
S. Rowe, Brandon S. Luber, Monique Makell, P. Brothers +8 more
2018Molecular Oncology43 citations Open access
Semantic Scholar
A uniform computational approach improved on existing pipelines to reveal microbiome biomarkers of non-response to immune checkpoint inhibitors
F. Shaikh, J. White, J. Gills, T. Hakozaki +11 more
2021Clinical Cancer Research37 citations Open access
Semantic Scholar
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
A. Silk, C. Barker, S. Bhatia, Kathryn Bollin +17 more
2022Journal for ImmunoTherapy of Cancer36 citations Open access
Semantic Scholar
Immune-related encephalitis after immune checkpoint inhibitor therapy
Monica W Buckley, Aanika Balaji Warner, Julie R. Brahmer, L. Cappelli +16 more
2024The Oncologist35 citations Open access
Semantic Scholar
Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)
G. Long, F. Hodi, E. Lipson, D. Schadendorf +16 more
2022Journal of Clinical Oncology35 citations
Semantic Scholar
BRAF‐V600 mutational status affects recurrence patterns of melanoma brain metastasis
Russell Maxwell, T. Garzon-Muvdi, E. Lipson, William H. Sharfman +5 more
2017International Journal of Cancer28 citations
Semantic Scholar
Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma
J. Deutsch, E. Lipson, L. Danilova, S. Topalian +11 more
2023Cell Reports Medicine26 citations Open access
Semantic Scholar
Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
E. Rodriguez, E. Lipson, K. Suresh, L. Cappelli +2 more
2019Human Pathology26 citations
Semantic Scholar
Kidney retransplantation after anti-programmed cell death-1 (PD-1)-related allograft rejection
E. Lipson, F. Naqvi, Manisha J. Loss, M. Schollenberger +3 more
2020American Journal of Transplantation25 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Taube×17
Invite
J. Taube — researcher profile on SciRah
W. Sharfman×13
Invite
W. Sharfman — researcher profile on SciRah
J. Naidoo×13
Invite
J. Naidoo — researcher profile on SciRah
S. Topalian×12
Invite
S. Topalian — researcher profile on SciRah

×11

Invite

P. Forde — researcher profile on SciRah

Invite

D. Pardoll — researcher profile on SciRah

L. Cappelli×10

Invite

L. Cappelli — researcher profile on SciRah

Invite

J. Brahmer — researcher profile on SciRah

Invite

S. Bhatia — researcher profile on SciRah

Invite

T. Cottrell — researcher profile on SciRah

Invite

F. Hodi — researcher profile on SciRah

Invite

Ami A. Shah — researcher profile on SciRah